Lohmann C M, League A A, Clark W S, Lawson D, DeRose P B, Cohen C
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Cytometry. 2000 Feb 15;42(1):61-6. doi: 10.1002/(sici)1097-0320(20000215)42:1<61::aid-cyto9>3.0.co;2-5.
Bcl-2 is a proto-oncogene which is involved in prolonging cell survival by inhibiting programmed cell death. Bax and bcl-x are members of the bcl-2 family; when overexpressed, they can counteract the ability of bcl-2 to inhibit apoptosis. This suggests a model in which the ratios of bcl-2 to bax and bcl-x can be used to determine response to therapy and prognosis. The expression of bcl-2, bax and bcl-x was studied in 50 ovarian carcinomas. The percentage of positive area immunostained (PPA) in the nucleus and cytoplasm of each ovarian carcinoma was quantitated in 15 high power fields by image cytometry. The ratios were obtained by dividing the PPA of bcl-2 by the PPA of bax and bcl-x. 17 of 50 ovarian carcinomas (34%) stained positively for bcl-2, 39 for bax (78%) and 47 for bcl-x (94%). Although there is no significant statistical correlation between expression of bcl-2, bax or bcl-x and grade (P = 0.15; P = 0. 47; P = 0.56), stage (P = 0.71; P = 0.6; P = 0.42), and overall or disease-free survival (P = 0.26; P = 0.55; P = 0.16), increased bcl-2 expression was demonstrated in patients with shortened overall and disease-free survival. Also, increased expression of bax and bcl-x was associated with increased overall and disease-free survival. Bcl-2:bax and bcl-2:bcl-x ratios less than 1 are associated with survival advantage, although not statistically significant (P = 0.83; P = 0.93). Image cytometric measurement of bcl-2, bax, and bcl-x expression is feasible. There is a tendency for their expression to correlate with prognosis in ovarian carcinomas.
Bcl-2是一种原癌基因，它通过抑制程序性细胞死亡来延长细胞存活时间。Bax和bcl-x是bcl-2家族的成员；当它们过度表达时，能够抵消bcl-2抑制细胞凋亡的能力。这提示了一种模型，其中bcl-2与bax和bcl-x的比例可用于确定对治疗的反应和预后。对50例卵巢癌患者的bcl-2、bax和bcl-x表达进行了研究。通过图像细胞术在15个高倍视野中对每例卵巢癌细胞核和细胞质中免疫染色阳性区域的百分比（PPA）进行定量。通过将bcl-2的PPA除以bax和bcl-x的PPA来获得比例。50例卵巢癌中有17例（34%）bcl-2染色阳性，39例（78%）bax染色阳性，47例（94%）bcl-x染色阳性。虽然bcl-2、bax或bcl-x的表达与分级（P = 0.15；P = 0.47；P = 0.56）、分期（P = 0.71；P = 0.6；P = 0.42）以及总生存期或无病生存期之间无显著统计学相关性（P = 0.26；P = 0.55；P = 0.16），但总生存期和无病生存期缩短的患者中bcl-2表达增加。此外，bax和bcl-x表达增加与总生存期和无病生存期延长相关。Bcl-2:bax和bcl-2:bcl-x比例小于1与生存优势相关，尽管无统计学显著性（P = 0.83；P = 0.93）。通过图像细胞术测量bcl-2、bax和bcl-x的表达是可行的。它们的表达在卵巢癌中有与预后相关的趋势。
